Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

J&J Slips As FDA Wants 60 Million Doses From Troubled Plant Discarded

Published 2021-06-11, 11:41 a/m
Updated 2021-06-11, 11:41 a/m
© Reuters

© Reuters

By Dhirendra Tripathi

Investing.com – Johnson & Johnson (NYSE:JNJ) shares fell more than 1% Friday after the Food and Drug Administration asked it to throw out 60 million doses of its Covid-19 vaccine that were made at a troubled Baltimore plant.

The FDA plans to allow about 10 million doses to be distributed in the U.S. or be sent to other countries, but with a warning that regulators cannot guarantee that Emergent Biosolutions (NYSE:EBS), the company that operates the plant, followed good manufacturing practices, NYT said.

The FDA had been trying to figure out the fate of at least 170 million doses of vaccine left in limbo after the discovery of a major production mishap involving two vaccines manufactured at the site.

More than 100 million doses of the J&J vaccine and at least 70 million doses of AstraZeneca's (NASDAQ:AZN) were put on hold after Emergent discovered in March that its workers had contaminated a batch of J&J with a key ingredient used to produce the U.K. company’s shots.

The Emergent plant remains shut.

J&J’s Covid vaccine is the only one in the world being given as a single shot. All others need two doses.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.